In Vivo: In rat model, TZ4M (2 and 3 mg/kg; ip; once daily for 8 days) inhibits Scopolamine (3 mg/kg; ip) induced neuronal damage in the hippocampus and apoptosis of hippocampus neurons and cortexin, and expands the number of mAChR M1 in neurons of the DG region and CA1 of the hippocampus and cortex. TZ4M is encountered to be BBB positive via CBligand-BBB forecast, which is needed for AChE inhibition.